Hypertriglyceridemia is a condition in which blood triglyceride (fat) levels are higher than usual. When triglyceride levels are more than or equivalent to 500 mg/dL, this condition arises. It can be caused by a variety of factors, including hereditary disorders, excessive drug use, smoking, metabolic conditions, stress, and physical inactivity, among others. Hypertriglyceridemia significantly increases the risk of atherosclerosis, acute pancreatitis, and a variety of cardiovascular illnesses (CVDs). Individuals can minimize their risk by changing their lifestyle and limiting their intake of sugar, processed carbohydrates, and alcohol. People can also boost their consumption of soy protein products, fatty fish, whole grains, quinoa, avocado, coconut oil, garlic, and cruciferous vegetables to drastically lower their triglyceride levels in the blood.
The growth of the hypertriglyceridemia therapeutics market is attributed to the increasing smoking and poor diets of individuals. According to OMR Research, these factors will significantly impact the market’s growth, which will grow at a CAGR of 4.3% during the forecast period (2023-2029).
Segments of the Market
The global hypertriglyceridemia therapeutics market is segmented on the basis of statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, and nutraceutical products. The nutraceutical products segment is further sub-segmented into vitamin B and omega-3 fatty acids. Among all these segments, the fibrates segment is witnessing the highest growth. Fibrates are medications to help lower triglyceride levels and increase the levels of high-density lipoprotein (HDL) cholesterol. Fibrates for hypertriglyceridemia are anticipated to grow at the highest CAGR of 5.6% during the forecast period. The market size for fibrates was $1.5 billion in 2021 and is estimated to reach $2.1 billion in 2028.
Recent Developments
Major players operating in the global hypertriglyceridemia therapeutics market include Abbott Laboratories, AstraZeneca PLC, Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., Lannett Company, Inc., Mitsubishi Tanabe Pharma, and Teva Pharmaceutical Industries Ltd., among others. Key players are focused on the development of novel drugs and launching these products in the market, which in turn create lucrative growth opportunities in the global hypertriglyceridemia therapeutics market. Some of the recent developments in the market include-
• In September 2022, AstraZeneca received approval from the US FDA for EPANOVA. EPANOVA is an omega-3 carboxylic acid that can be used as a dietary supplement to help adults lower their triglyceride levels. The drug was created specifically to treat severe hypertriglyceridemia in the general population.
• In April 2022, AstraZeneca planned to open a new site at the Cambridge, MA, life sciences and innovation hub. It is a strategic R&D center for AstraZeneca as well as Alexion’s new corporate headquarters, and this new site will bring together approximately 1,500 R&D, commercial, and corporate colleagues into a single purpose-built space.
• In April 2022, Amarin Corporation plc announced its partner HLS Therapeutics had completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA), under which VASCEPA (icosapent ethyl) would qualify for public market reimbursement in Canada. VASCEPA received the drug’s initial FDA approval indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia.
• In September 2021, Arrowhead Pharmaceuticals, Inc., announced that it had dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia. ARO-APOC3 is the company’s investigational RNA interference (RNAi) therapeutic that is being developed as a treatment for patients with severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS).
Conclusion
There are various factors that are aiding in the global hypertriglyceridemia market, for instance, the adoption of sedentary lifestyles, the growing prevalence of obesity and CVD, and others. Obesity raises the chance of getting diabetes as well as CVD, notably heart failure and coronary heart disease. Obesity increases the risk of CVD because it alters body composition, which can impact hemodynamics and may alter the anatomy of the heart. As a result, the rising incidence of obesity and CVDs is one of the primary reasons driving worldwide market growth. The World Health Organization (WHO) estimates that around 38.9% of the world's population is obese or overweight. Furthermore, according to data given by the American Heart Association, CVD caused deaths every 36 seconds in the US in 2021. Due to all such reasons, several leading market companies are extensively investing in the R&D and commercialization of innovative medications for the treatment of hypertriglyceridemia, which is projected to drive market growth over the forecast period. For instance, in July 2019, Sun Pharmaceuticals, Inc. launched Rosuvastatin, an Ezallor Sprinkle, in the US market to treat hypertriglyceridemia. The drug is available on the market in the form of capsules and can be consumed as an adjunct to the diet. Additionally, the drug is also prescribed to adults suffering from type 3 hyperlipoproteinemia and ongoing lipid-lowering treatment.